Galena Biopharma, Inc. (NASDAQ:GALE) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -9.34% to 0.74 with around 4.18 Million shares have changed hands in this session. Pomerantz LLP is investigating claims on behalf of investors of Galena Biopharma, Inc. (NASDAQ:GALE). The investigation concerns whether Galena and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On March 10, 2016, the Company disclosed that “[a] federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes,” and that the Company had received a trial subpoena for documents in connection with that investigation.
The Company further disclosed that “other governmental agencies may be investigating our Abstral promotion practices,” and that “on December 16, 2015, we received a subpoena issued by the U.S. Attorney’s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral.” The stock is going forward its fifty-two week low with -8.22% and lagging behind from its 52-week high price with -98.51%.
Similar, the positive performance for the quarter recorded as -80.44% and for the year was -95.11%, while the YTD performance remained at -61.68%. GALE has Average True Range for 14 days of 0.24.
North European Oil Royalty Trust (NYSE:NRT) [Trend Analysis] retains strong position in active trade, as shares scoring -1.48% to $7.99 in a active trade session, while looking at the shares volume, around 53206 shares have changed hands in this session. North European Oil Royalty Trust (NYSE: NRT) declared the net income and results for the first quarter of fiscal 2017 which appear below compared with the first quarter of fiscal 2016. Total royalty income reflects the inclusion of adjustments made by the operating companies based upon their corrected royalty calculations for prior periods as well as the inclusion of Mobil sulfur royalties. The total adjustments for the first quarter of fiscal 2017 surged total royalty income by $23,796. By comparison, in the first quarter of fiscal 2016 total royalty income was reduced by $560,902.
The Trust receives nearly all of its royalties under two royalty contracts. The Mobil Contract, the higher royalty rate contract, covers gas sales from the western half of the Oldenburg concession. The OEG Contract, the lower royalty rate contract, covers gas sales from the entire Oldenburg concession. The firm has institutional ownership of 9.90%, while insider ownership included 0.47%.